Coherus Biosciences Inc (NASDAQ:CHRS) price closed lower on Friday, April 12, dropping -7.47% below its previous close.
A look at the daily price movement shows that the last close reads $2.41. The company’s 5Y monthly beta was ticking 0.51. Taking into account the 52-week price action we note that the stock hit a 52-week high of $8.65 and 52-week low of $1.43. The stock subtracted -3.04% on its value in the past month.
Coherus Biosciences Inc, which has a market valuation of $248.33 million, is expected to release its quarterly earnings report May 06, 2024 – May 10, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give CHRS a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 75% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
The overview shows that CHRS’s price is at present -6.13% off the SMA20 and -6.73% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 42.31, with weekly volatility standing at 7.23%. The indicator jumps to 7.93% when calculated based on the past 30 days. Coherus Biosciences Inc (NASDAQ:CHRS)’s beta value is holding at 0.51, while the average true range (ATR) indicator is currently reading 0.18. An analysis of the Coherus Biosciences Inc (NASDAQ:CHRS) stock in terms of its daily trading volume indicates that the 3-month average is 3.49 million.
Current records show that the company has 112.22M in outstanding shares. The insiders’ percentage holdings are 4.67% of outstanding shares while the percentage share held by institutions stands at 76.56%. But the -33.03% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
